-- 根據週三提交給澳洲證券交易所的文件顯示，Mesoblast（ASX：MSB）已完成一項針對退化性椎間盤疾病相關慢性腰痛的 rexlemestrocel-L 治療藥物的 III 期臨床試驗的招募目標，至少招募了 300 名患者。 這項安慰劑對照研究將隨機分配患者接受單次椎間盤內注射該公司專有的同種異體間質細胞療法或假注射，療程為 12 個月。根據文件，研究的主要終點是腰痛緩解程度的顯著差異。 該試驗的次要終點包括功能改善、生活品質提高以及停用包括鴉片類藥物在內的止痛藥物。 該公司預計將於 2027 年年中公佈初步結果。 Mesoblast 的股價在周三的交易中上漲了近 5%。
Related Articles
Asia
Willfar Information Technology's Q1 2026 Profit Rises 6%
Willfar Information Technology (SHA:688100), a 59.55%-owned subsidiary of Wasion Holdings (HKG:3393), reported 148.3 million yuan in attributable profit for the first quarter of 2026, up 6.4% from 139.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Revenue fell 4.2% year on year to 531.9 million yuan, figures showed.
$HKG:3393$SHA:688100
Asia
Zhongjin Gold's 2025 Profit Jumps 46%
Zhongjin Gold's (SHA:600489) attributable profit rose 46% to 4.93 billion yuan in 2025 from 3.39 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the non-ferrous metals miner increased to 1.02 yuan from 0.70 yuan in the previous year.Operating revenue grew 21% year over year to 79.1 billion yuan from 65.6 billion yuan.
$SHA:600489
Asia
Jinduicheng Molybdenum's Q1 Profit Jumps 33%, Revenue Rises 27%
Jinduicheng Molybdenum's (SHA:601958) net profit attributable to shareholders in the first quarter jumped 33% year on year to 901.6 million yuan, or 0.279 yuan per share, according to a Wednesday disclosure on Shanghai filing.The attributable profit a year earlier was almost 678 million yuan, or 0.210 yuan per share.Operating revenue rose 27% to 4.16 billion yuan from 3.28 billion yuan in the previous year.The Chinese molybdenum miner's shares jumped less than 7% at the close.
$SHA:601958